Oddo BHF Asset Management Sas Acquires New Stake in Abivax SA Sponsored ADR $ABVX

Oddo BHF Asset Management Sas acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 79,350 shares of the company’s stock, valued at approximately $10,701,000. Oddo BHF Asset Management Sas owned about 0.10% of Abivax as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. TCG Crossover Management LLC raised its stake in Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after purchasing an additional 1,055,000 shares during the last quarter. UBS Group AG raised its stake in Abivax by 2,561.0% in the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after purchasing an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in Abivax in the 3rd quarter valued at $263,698,000. Morgan Stanley raised its stake in Abivax by 114.3% in the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after purchasing an additional 1,681,277 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new position in Abivax in the 3rd quarter valued at $132,800,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Stock Performance

Shares of ABVX opened at $98.26 on Tuesday. The stock has a 50-day simple moving average of $115.61 and a 200-day simple moving average of $118.86. The stock has a market capitalization of $7.84 billion, a PE ratio of -18.86 and a beta of 0.69. Abivax SA Sponsored ADR has a 1 year low of $5.69 and a 1 year high of $148.83.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. Analysts predict that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Wall Street Analysts Forecast Growth

ABVX has been the subject of a number of recent research reports. Barclays raised their target price on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Wolfe Research set a $136.00 price objective on Abivax in a research report on Wednesday, June 3rd. BTIG Research restated a “buy” rating and set a $150.00 target price on shares of Abivax in a report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a report on Monday, April 20th. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $130.08.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.